Announced
Completed
Financials
Tags
invitro diagnostic systems
Private
Acquisition
Majority
Single Bidder
Private Equity
Medical Services
Friendly
Cross Border
France
Completed
Synopsis
Bruker, an international life science research and diagnostics solutions provider, completed the acquisition of ELITech, a global manufacturer of in-vitro diagnostics, from PAI Partners, a private equity firm, for $774m. "We are very pleased to welcome ELITech to Bruker. The ELITech molecular diagnostics sample-to-answer platforms for viral infection and other esoteric MDx assays complement our MALDI Biotyper® platform for bacterial and fungal identification. The combined offerings establish Bruker as an innovative and growing infectious disease specialist in the in-vitro diagnostics (IVD) market,” Frank H. Laukien, Bruker President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.